5 Hydroxytryptamine Receptor 1F (5 Ht1F) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The 5-HT1F receptor is a serotonin receptor subtype belonging to the G protein-coupled receptor (GPCR) superfamily. It is negatively coupled to adenylyl cyclase via Gi/o proteins, resulting in decreased cAMP production. The 5-HT1F receptor is expressed in the trigeminal ganglion, cortex, hippocampus, and dorsal raphe nucleus, where it modulates neurotransmitter release and participates in migraine pathophysiology. [1]
5-HT1F is a typical GPCR with: [2]
Key structural features: [3]
5-HT1F receptors are key in migraine: [^5]
In the CNS, 5-HT1F modulates: [^6]
In hippocampus and cortex:
5-HT1F agonists are used for:
The study of 5 Hydroxytryptamine Receptor 1F (5 Ht1F) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The 5-HT1F receptor is expressed throughout the central nervous system with particularly high levels in:
The 5-HT1F receptor has emerged as a promising drug target:
Migraine: Frovatriptan and lasmiditan are 5-HT1F agonists used for acute migraine treatment. Unlike triptans, they lack significant vasoconstrictive effects.
Neuroprotection: 5-HT1F activation may provide neuroprotective effects through:
Potential for Neurodegeneration:
5-HT1F is a Gi/o-coupled receptor that:
Selective 5-HT1F agonists offer advantages:
Berger M, et al. 5-HT1F receptors in the CNS. 2009. ↩︎
Hargreaves R, et al. Triptans and 5-HT1F agonists. 2022. ↩︎
Lucas RJ. 5: Peroutka SJ. 1997. ↩︎